GLP1R and type 2 diabetes mellitus: A number of GLP-1 receptor agonists have already been approved by the Food and Drug Administration (FDA) for type 2 diabetes treatment, including exenatide, liraglutide, semaglutide, lixisenatide, dulaglutide, albiglutide, and others.